ImmunityBio, Inc.
ImmunityBio Receives FDA Approval for ANKTIVA to Treat BCG-Unresponsive NMIBC
Summary
On April 22, 2024, ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. ANKTIVA, a first-in-class IL-15 agonist immunotherapy, demonstrated a 62% complete response rate, with the duration of complete response exceeding 47 months. The combination therapy is expected to be available in the U.S. by mid-May 2024. Additionally, the company is considering increasing the number of shares authorized for issuance under its 2015 Equity Incentive Plan, subject to stockholder approval.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement